XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting (Selected Financial Information by Reporting Segment) (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
segment
Sep. 30, 2022
USD ($)
Segment Reporting Information [Line Items]        
Number of Reportable Segments | segment     2  
Net revenues:        
Total net revenues $ 180,556 $ 120,129 $ 466,290 $ 363,964
Gross profit (loss):        
Gross Profit 108,403 58,510 254,981 177,692
Operating expenses 35,725 35,282 111,974 108,027
Income from operations 72,678 23,228 143,007 69,665
Non-operating income (expenses) (9,041) (632) (12,993) 5,115
Income (loss) before income taxes 63,637 22,596 130,014 74,780
Finished Pharmaceutical Products Segment        
Net revenues:        
Total net revenues 176,366 117,120 455,242 353,789
Gross profit (loss):        
Gross Profit 109,499 61,439 262,742 185,462
Active Pharmaceutical Ingredient Segment [Member]        
Net revenues:        
Total net revenues 4,190 3,009 11,048 10,175
Gross profit (loss):        
Gross Profit $ (1,096) $ (2,929) $ (7,761) $ (7,770)